Blog

Zenagamtide: Novo's One-Molecule GLP-1 and Amylin Bet

Novo renamed amycretin and its phase 2b data showed up to 14.6% weight loss in type 2 diabetes from a single molecule. Here is why the structural bet matters.

If you have been following the obesity pipeline, you have probably seen the name amycretin. Novo Nordisk has quietly renamed it zenagamtide, and the phase 2 data now on the table makes it one of the more interesting structural bets in the entire field: a single molecule that activates both GLP-1 receptors and amylin receptors.

Everyone else is stacking. Novo is building one molecule that does two jobs. Here is what the data shows and why the difference matters.

What the Research Says

The headline readouts came at the American Diabetes Association Scientific Sessions in June 2026 and in published form through mid-year. From Novo Nordisk’s phase 2 announcements and the phase 2b poster data presented at ADA:

  • Subcutaneous zenagamtide produced up to -14.5% weight loss at 36 weeks (from a mean baseline of 99.2 kg), versus -2.6% on placebo, in adults with type 2 diabetes
  • Oral zenagamtide produced up to -10.1% (from a mean baseline of 101.1 kg) versus -2.5% on placebo - notable because oral peptide delivery usually costs a large efficacy penalty
  • The phase 2b dose escalation (0.4 mg through 40 mg) showed a clean dose-response for weight: -4.35% at the lowest dose through -14.60% at 40 mg
  • Doses in the subcutaneous and oral phase 2 trials showed no weight-loss plateau at week 36 - the curve was still falling when the trial ended
  • A1C reductions were statistically significant across all doses in the type 2 diabetes population

A Lancet comment published July 30, 2026 (DOI: 10.1016/S0140-6736(26)01487-X) framed the compound as the first-in-class unimolecular GLP-1 and amylin receptor agonist for glucose and weight control, alongside the first-in-human safety data published in The Lancet last year.

Why One Molecule Versus Two Is the Argument

Novo’s own CagriSema - cagrilintide plus semaglutide - already proved the amylin-plus-GLP-1 concept, hitting 22.7% weight loss at 68 weeks in REDEFINE 1. So why build zenagamtide at all?

The engineering logic: a unimolecular co-agonist means one pharmacokinetic profile, one manufacturing pathway, and one dosing schedule that was designed together rather than merged. It also opens the oral door. Oral zenagamtide hitting -10.1% in phase 2 is the sleeper result here, because amylin-GLP-1 co-agonism delivered as a tablet would sidestep the injection burden that CagriSema carries.

The risks are equally structural. Co-agonist design means you cannot tune one receptor’s exposure without moving the other - if a participant tolerates the amylin activity poorly, there is no dose-splitting option the way there is with a free combination like eloraTZP or CagriSema. Whether the fixed ratio lands in the right place for most people is exactly what phase 3 will test, and no phase 3 readout exists yet.

Novo is presenting further zenagamtide-related work at EASD in Milan this week, including mechanistic work on appetite and food-cue reactivity, so expect the picture to sharpen over the coming days.

The Australian Angle

Zenagamtide has no regulatory existence in Australia - it is an investigational compound with no TGA submission, and like everything discussed this week at EASD, it is years from any scheduling decision. The interesting local signal is strategic: Novo’s Australian incretin position (Ozempic on the PBS for type 2 diabetes, Wegovy PBS-listed this year) is under commercial pressure from Lilly’s approvals, and zenagamtide is the clearest sign of where Novo is placing its next-generation bet.

For the research interest community, the name change is worth noting for practical reasons - grey market listings have already started appearing under both names, and neither has ever been made available outside a Novo trial. Anything sold under either name is unverified at best. See our CagriSema overview for how the amylin-plus-incretin thesis has performed so far, and the semaglutide page for the foundation it builds on.

Sources

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.